Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis-Reference-Cited by-同舟云学术

Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis

Published:2020 Issue:4 Volume:43 Page:160-169
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Zhuo Ze-Guo,Zhu Yun-Ke,Deng Han-Yu,Li Gang,Luo Jun,Alai Gu-Ha,Lin Yi-Dan

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al.; National comprehensive cancer network. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb;13(2):194–227.

2. Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013 Aug;24(8):2068–73.

3. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011 May;253(5):934–9.

4. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008 Mar;14(5):1291–5.

5. Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, et al. Biological and predictive role of ERCC1 polymorphisms in cancer. Crit Rev Oncol Hematol. 2017 Mar;111:133–43.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long noncoding RNAs as potential targets for overcoming chemoresistance in upper gastrointestinal cancers;Biomedicine & Pharmacotherapy;2024-10

2. Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer;Frontiers in Immunology;2024-08-13

3. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma;Therapeutic Advances in Medical Oncology;2023-01

4. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs;Cancer Letters;2022-02

5. Development of Novel Cancer Biomarkers for Diagnosis and Prognosis;Cancer Biomarkers in Diagnosis and Therapeutics;2022